CoChat

Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease

Open access
Mast, Natalia, Saadane, Aicha, Valencia-Olvera, Ana, Constans, James, Maxfield, Erin, Arakawa, Hiroyuki, Li, Young, Landreth, Gary, Pikuleva, Irina A. · 2017 · Neuropharmacology
Cited by 107

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

&NA; Cytochrome P450 46A1 (CYP46A1 or cholesterol 24‐hydroxylase) controls cholesterol elimination from the brain and plays a role in higher order brain functions. Genetically enhanced CYP46A1 expression in mouse models of Alzheimer's disease mitigates the manifestations of this disease. We enhanced CYP46A1 activity pharmacologically by treating 5XFAD mice, a model of rapid amyloidogenesis, with a low dose of the anti‐HIV medication efavirenz. Efavirenz was administered from 1 to 9 months of age, and mice were evaluated at specific time points. At one month of age, cholesterol homeostasis was already disturbed in the brain of 5XFAD mice. Nevertheless, efavirenz activated CYP46A1 and mouse cerebral cholesterol turnover during the first four months of administration. This treatment time also reduced amyloid burden and microglia activation in the cortex and subiculum of 5XFAD mice as well as protein levels of amyloid precursor protein and the expression of several genes involved in inflammatory response. However, mouse short‐term memory and long‐term spatial memory were impaired, whereas learning in the context‐dependent fear test was improved. Additional four months of drug administration (a total of eight months of treatment) improved long‐term spatial memory in the treated as compared to the untreated mice, further decreased amyloid‐&bgr; content in 5XFAD brain, and also decreased the mortality rate among male mice. We propose a mechanistic model unifying the observed efavirenz effects. We suggest that CYP46A1 activation by efavirenz could be a new anti‐Alzheimer's disease treatment and a tool to study and identify normal and pathological brain processes affected by cholesterol maintenance. HighlightsCYP46A1 activity was enhanced pharmacologically by the anti‐HIV drug efavirenz.CYP46A1 activation promoted cholesterol turnover in the brain of 5XFAD mice.CYP46A1 activation reduced amyloid‐&bgr; burden in the brain of 5XFAD mice.CYP46A1 activation reduced microglial immunoreactivity in the brain of 5XFAD mice.Efavirenz effects on behavior of 5XFAD mice were task‐ and treatment time‐specific.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2017.06.026

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 107

Metadata

Authors
Mast, N., Saadane, A., Valencia-Olvera, A., Constans, J., Maxfield, E., Arakawa, H., Li, Y., Landreth, G., & Pikuleva, I. A.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2017-09
Volume
123
Pages
465-476
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2700577086
Cited by
107
References
27
FWCI
6.01
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.neuropharm.2017.06.026
The paper
Mast, N., Saadane, A., Valencia-Olvera, A., Constans, J., Maxfield, E., Arakawa, H., Li, Y., Landreth, G., & Pikuleva, I. A. (2017). Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2017.06.026

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.